Publications & Presentations
Transparency is a fundamental principle of the operations of the CBER Surveillance Program including the BEST Initiative, Sentinel System, CMS collaboration, and others. Knowledge acquired from the surveillance activities is placed in the public domain. To accomplish this aim, information concerning surveillance activities will be made available on the BEST website and other locations when appropriate.
Most Recent Publications & Presentations Assessments
Title
Date
Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases
Lancet. 2022 Jun 11 (pdf)
- Lancet. Supplementary. 2022 Jun 11 (pdf)
- Lancet. Commentary. 2022 Jun 11 (pdf)
- FDA BEST Lancet 2022-All Files (zip)
Show more +
This publication also includes a supplementary appendix and commentary.
06/11/2022
Risk, myocarditis, pericarditis, COVID-19 mRNA vaccinations, administrative claims
Vaccine exposure during pregnancy among privately and publicly insured women in the United States, 2016–2018
Vaccine. 2021 Oct 01 (pdf)
10/01/2021
Vaccine exposure, pregnancy, Insured women
Acute myocardial infarction: Development and application of an ICD-10-CM-based algorithm to a large U.S. healthcare claims-based database
PLoS One. 2021 Jul 01 (pdf)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253580
07/01/2021
Acute myocardial infarction ICD-10, administrative claims, algorithm
An FDA-CBER Update on Surveillance, Epidemiology and Risk Management Approaches for Biologics
01/29/2020
DIA PV and Risk Management Strategies Conference
Biologics Effectiveness and Safety (BEST) Initiative: Sentinel Public Meeting 2019
04/03/2019
Sentinel Public Meeting 2019
Biologics Effectiveness and Safety (BEST) Initiative: First Year
10/12/2018
OHDSI Symposium 2018